AAIC 2026 showed a primary-care Alzheimer's blood test — a blood measure of proteins linked to Alzheimer's — reached 93% accuracy, nearly matching specialists. For memory clinic patients, that means earlier answers in primary care and clearer referrals for scans, treatment review, or other causes. Led by Lund University neurologist Sebastian Palmqvist, the study enrolled people with mild impairment or dementia in primary and specialty care. Doctors recorded a diagnosis before blood results, then updated it after seeing them.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the study blood test measured
- How much primary-care diagnosis improved
- Which tests received FDA clearance
- Why scans and spinal-fluid tests still matter
- What to do before a memory-clinic referral
What the study blood test measured
According to Clinical Lab Products in its test report, the study used C2N's PrecivityAD2 blood test to assess Alzheimer's brain pathology. It measures amyloid-beta ratios and phosphorylated-tau217 in blood.
Amyloid and tau are proteins tied to Alzheimer's brain changes. The test combines them into one signal of likely pathology, not a stand-alone diagnosis.
How much primary-care diagnosis improved
According to the Alzheimer's Association/AAIC in its AAIC release, primary-care accuracy rose from 65% before blood results to 93% after. Specialists reached about 90-94% after results, so the gap nearly closed.
The same Association release reports physicians changed the diagnosis in about one-third of patients. They changed planned workup or care in over half, with greatest value in ruling out Alzheimer's in primary care.
Which tests received FDA clearance
According to Patient Care Online in its FDA clearance report, FDA cleared C2N PrecivityAD2 on Aug. 20, 2026. It is an adjunct test for symptomatic adults age 40 and older. It reports an amyloid probability score from 0 to 100.
Reported predictive values were 97.6% positive and 93.1% negative. According to AJMC in its FDA clearance report, FDA cleared Roche Elecsys pTau217 plasma on Aug. 24-25, 2026. It is for symptomatic adults age 55 and older. AJMC describes it as the first single-biomarker test to both rule in and rule out amyloid across primary and specialty care.
Why scans and spinal-fluid tests still matter
According to Patient Care Online, cleared tests require cognitive symptoms plus clinical assessment. They cannot screen people without symptoms and cannot diagnose alone.
Intermediate or likely-positive blood results still need PET or spinal-fluid confirmation. A negative result helps redirect care toward non-Alzheimer's causes.
What to do before a memory-clinic referral
Ask your primary-care doctor whether a cleared blood test fits your symptoms and history. Bring a symptom timeline, medication list, and a family member who knows daily changes.
Use this check at the visit: Bring the blood-test report to the memory clinic, with scores and date. Ask how the result changes next tests or follow-up timing.
- Note when memory or thinking changes began
- List prescription drugs, sleep aids, and alcohol use
- Ask when referral, PET, or spinal-fluid testing is needed
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Result Interpretation Questions for Memory Clinic Patients
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Memory Clinic Patients Can Compare Testing Options
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Result Interpretation Questions for Memory Clinic Patients





